(MENAFNEditorial) Radiant Insights has announced the addition of "Global Immune Checkpoint Inhibitors Market Outlook 2022" Market Research report to their database According to the report 'Global Outlook 2022, the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors.
Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immune therapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history of hard-to-treat cancers by producing substantial clinical benefits for certain tumor types and patients. Some of these checkpoints are called PD-1, PD-L1, and CTLA-4 receptors. They work by activating the body's immune system against antigens expressed on tumor cells. Drugs that target these checkpoints hold great promise and have generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.
The report 'Global Immune Checkpoint Inhibitors Market Outlook 2022 is available now at
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors.
The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch their products.
Request a Free Sample Copy of this Report @
On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
The later part of the report discusses some of the prominent players in the global immune checkpoint inhibitors market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immune checkpoint inhibitor is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.
Read more related reports by Radiant Insights:
• Protein Hydrolysate Industry-
In this report, the global Protein Hydrolysate market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Protein Hydrolysate in these regions, from 2013 to 2025 (forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Bi-Specific Antibodies Market-
Bi-specific antibody is one of the most potentially powerful tools which have emerged in the biopharmaceutical industry. The bi-specific antibodies intend to provide the next generation of targeted biologics by engaging two different targets simultaneously. These drugs offer several advantages over traditional treatment options for various diseases such as cancer. They have fewer side effects due to high specificity towards disease target. These antibodies are of particular importance for patients who experience recurrence or resistance to drugs.
Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist - USA
Email:
Phone: (415) 349-0054, Toll Free: 1-888-928-9744
Address:201 Spear Street 1100, Suite 3036
City: San Francisco
State: California
Country: United States
Website:
MENAFN2302201800703268ID1096506278
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.